Stratos Wealth Partners LTD. Makes New Investment in Anavex Life Sciences Corp. $AVXL

Stratos Wealth Partners LTD. acquired a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 26,600 shares of the biotechnology company’s stock, valued at approximately $245,000.

Other large investors also recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. bought a new stake in Anavex Life Sciences during the first quarter worth approximately $102,000. KLP Kapitalforvaltning AS bought a new stake in Anavex Life Sciences during the first quarter worth approximately $141,000. Yukon Wealth Management Inc. bought a new stake in Anavex Life Sciences during the first quarter worth approximately $147,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Anavex Life Sciences by 703.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,792 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 16,453 shares during the last quarter. Finally, SeaCrest Wealth Management LLC increased its stake in Anavex Life Sciences by 11.9% during the second quarter. SeaCrest Wealth Management LLC now owns 19,700 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 2,100 shares during the last quarter. 31.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, October 1st. Jones Trading cut Anavex Life Sciences from a “buy” rating to a “hold” rating in a research note on Friday. Wall Street Zen cut Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 23rd. HC Wainwright reaffirmed a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Friday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $44.00.

Anavex Life Sciences Stock Down 1.5%

Shares of NASDAQ:AVXL opened at $8.61 on Friday. Anavex Life Sciences Corp. has a 52-week low of $5.22 and a 52-week high of $14.44. The stock has a market cap of $739.51 million, a P/E ratio of -15.11 and a beta of 0.83. The business’s 50 day moving average is $9.20 and its 200 day moving average is $9.37.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, sell-side analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.